Telehealth firm Hims & Hers said it will stop offering a compounded version of Novo Nordisk’s Wegovy following legal pressure from regulators and industry challengers. The company faced federal scrutiny over plans to sell an unapproved compounded GLP‑1 pill and moved to pause the product amid escalating threats of enforcement. Novo Nordisk and US regulators raised legal objections to the product’s authorization and intellectual‑property implications. Hims’ reversal highlights regulatory risk in rapid attempts to commercialize compounded versions of branded GLP‑1 medicines and underscores the legal scrutiny that telehealth and compounding pathways face when they overlap with high‑value branded therapies.